Go to Liminal BioSciences Q4 and Year-End Results Conference Call on Thursday March 25, 2021 8:30 AM ESTView Now
Other content in this Stream
Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results
LMNL focused on continued advancement of its small molecule therapeutics platform including development of fezagepras and evaluating strategic alternatives for its plasma-derived therapeutics entity.
Prometic Plasma Resources (USA) Inc., has received U.S. Food and Drug Administration (“FDA”) approval for its plasma collection center located in Amherst, NY.
LMNL today announced that the first subject has been dosed in the Company’s fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers.